MacroGenics, Inc.
US ˙ NasdaqGS ˙ US5560991094

Introduction

This page provides a comprehensive analysis of the known insider trading history of David C Stump. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate David C Stump has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:RGNX / REGENXBIO Inc. Director 19,054
US:MGNX / MacroGenics, Inc. Director 11,000
Director 0
Director 60,000
US:DNDN / Director 82,047
US:HGSI / Human Genome Sciences Inc Exec. Vice President 0
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by David C Stump. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases MGNX / MacroGenics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in MGNX / MacroGenics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

MGNX / MacroGenics, Inc. Insider Trades
Insider Sales MGNX / MacroGenics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in MGNX / MacroGenics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

MGNX / MacroGenics, Inc. Insider Trades
Insider Purchases RGNX / REGENXBIO Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in MGNX / MacroGenics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

RGNX / REGENXBIO Inc. Insider Trades
Insider Sales RGNX / REGENXBIO Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in MGNX / MacroGenics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

RGNX / REGENXBIO Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by David C Stump as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-06-03 2025-05-30 4 RGNX REGENXBIO Inc.
Common Stock
A - Award 7,768 19,054 68.83
2025-05-22 2025-05-20 4 MGNX MACROGENICS INC
Common Stock
M - Exercise 6,500 11,000 144.44
2024-06-04 2024-05-31 4 RGNX REGENXBIO Inc.
Common Stock
A - Award 4,790 11,286 73.74
2024-05-22 2024-05-20 4 MGNX MACROGENICS INC
Common Stock
M - Exercise 4,500 4,500
2023-06-06 2023-06-02 4 RGNX REGENXBIO Inc.
Common Stock
A - Award 3,486 6,496 115.81
2022-06-07 2022-06-03 4 RGNX REGENXBIO Inc.
Common Stock
A - Award 3,010 3,010
2022-05-23 2022-05-19 4 MGNX MACROGENICS INC
Stock Option (right to buy)
A - Award 18,000 18,000
2021-06-08 2021-06-04 4 RGNX REGENXBIO Inc.
Stock Option (Right to Buy)
A - Award 10,000 10,000
2021-05-17 2021-05-13 4 MGNX MACROGENICS INC
Stock Option (right to buy)
A - Award 15,000 15,000
2020-07-02 2020-07-02 4 PTLA PORTOLA PHARMACEUTICALS INC
Stock Option (Right to Buy)
D - Sale to Issuer -44,991 0 -100.00
2020-07-02 2020-07-02 4 PTLA PORTOLA PHARMACEUTICALS INC
Stock Option (Right to Buy)
D - Sale to Issuer -11,377 0 -100.00 0.06 -683
2020-07-02 2020-07-02 4 PTLA PORTOLA PHARMACEUTICALS INC
Restricted Stock Units
D - Sale to Issuer -7,281 0 -100.00 18.00 -131,058
2020-07-02 2020-07-02 4 PTLA PORTOLA PHARMACEUTICALS INC
Common Stock
D - Sale to Issuer -13,194 0 -100.00 18.00 -237,492
2020-07-01 2020-06-30 4 SNSS SUNESIS PHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 60,000 60,000
2020-06-15 2020-06-12 4 PTLA PORTOLA PHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 11,377 11,377
2020-06-15 2020-06-12 4 PTLA PORTOLA PHARMACEUTICALS INC
Common Stock
A - Award 7,281 20,475 55.18
2020-06-02 2020-05-29 4 RGNX REGENXBIO Inc.
Stock Option (Right to Buy)
A - Award 10,000 10,000
2020-05-15 2020-05-14 4 MGNX MACROGENICS INC
Stock Option (right to buy)
A - Award 15,000 15,000
2019-07-02 2019-06-28 4 SNSS SUNESIS PHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 60,000 60,000
2019-06-17 2019-06-13 4 PTLA PORTOLA PHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 6,991 6,991
2019-06-17 2019-06-13 4 PTLA PORTOLA PHARMACEUTICALS INC
Common Stock
A - Award 4,194 13,194 46.60
2019-06-04 2019-05-31 4 RGNX REGENXBIO Inc.
Stock Option (Right to Buy)
A - Award 10,000 10,000
2019-05-20 2019-05-16 4 MGNX MACROGENICS INC
Stock Option (right to buy)
A - Award 10,000 10,000
2018-07-03 2018-06-29 4 SNSS SUNESIS PHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 25,000 25,000
2018-06-08 2018-06-08 4 PTLA PORTOLA PHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 6,000 6,000
2018-06-08 2018-06-08 4 PTLA PORTOLA PHARMACEUTICALS INC
Common Stock
A - Award 3,000 9,000 50.00
2018-05-30 2018-05-25 4 RGNX REGENXBIO Inc.
Stock Option (Right to Buy)
A - Award 12,500 12,500
2018-05-21 2018-05-17 4 MGNX MACROGENICS INC
Stock Option (right to buy)
A - Award 10,000 10,000
2017-06-19 2017-06-16 4 PTLA PORTOLA PHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 6,000 6,000
2017-06-19 2017-06-16 4 PTLA PORTOLA PHARMACEUTICALS INC
Common Stock
A - Award 3,000 3,000
2017-06-02 2017-05-31 4 SNSS SUNESIS PHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 25,000 25,000
2017-05-26 2017-05-24 4 RGNX REGENXBIO Inc.
Stock Option (Right to Buy)
A - Award 12,500 12,500
2017-05-22 2017-05-18 4 MGNX MACROGENICS INC
Stock Option (right to buy)
A - Award 10,000 10,000
2016-07-05 2016-06-30 4 SNSS SUNESIS PHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 50,000 50,000
2016-06-20 2016-06-17 4 PTLA PORTOLA PHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 6,000 6,000
2016-06-20 2016-06-17 4 PTLA PORTOLA PHARMACEUTICALS INC
Common Stock
A - Award 3,000 3,000
2016-06-02 2016-06-01 4 RGNX REGENXBIO Inc.
Stock Option (Right to Buy)
A - Award 12,500 12,500
2016-05-20 2016-05-18 4 MGNX MACROGENICS INC
Stock Option (right to buy)
A - Award 8,500 8,500
2015-10-15 2015-10-14 4 RGNX REGENXBIO Inc.
Stock Option (Right to Buy)
A - Award 25,000 25,000
2015-09-25 2015-09-24 4 PTLA PORTOLA PHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 20,000 20,000
2015-07-01 2015-06-30 4 SNSS SUNESIS PHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 40,000 40,000
2015-05-21 2015-05-20 4 MGNX MACROGENICS INC
Stock Option (right to buy)
A - Award 8,500 8,500
2014-07-01 2014-06-30 4 SNSS SUNESIS PHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 20,000 20,000
2014-06-09 2014-06-05 4 MGNX MACROGENICS INC
Stock Option (right to buy)
A - Award 6,924 6,924
2014-01-07 2014-01-03 4 DNDN DENDREON CORP
Common Stock
A - Award 25,000 82,047 43.82
2013-10-11 2013-10-09 4 MGNX MACROGENICS INC
Stock Option (right to buy)
A - Award 13,849 13,849
2013-07-02 2013-06-28 4 SNSS SUNESIS PHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 20,000 20,000
2013-01-07 2013-01-03 4 DNDN DENDREON CORP
Common Stock
A - Award 25,000 57,047 78.01
2012-08-01 2012-07-30 4 HGSI HUMAN GENOME SCIENCES INC
Employee Stock Option - Right to Buy
D - Sale to Issuer -104,304 0 -100.00 14.25 -1,486,332
2012-08-01 2012-07-30 4 HGSI HUMAN GENOME SCIENCES INC
Employee Stock Option - Right to Buy
D - Sale to Issuer -100,000 0 -100.00 14.25 -1,425,000
2012-08-01 2012-07-30 4 HGSI HUMAN GENOME SCIENCES INC
Employee Stock Option - Right to Buy
D - Sale to Issuer -87,390 0 -100.00 14.25 -1,245,308
2012-08-01 2012-07-30 4 HGSI HUMAN GENOME SCIENCES INC
Employee Stock Option - Right to Buy
D - Sale to Issuer -108,000 0 -100.00 14.25 -1,539,000
2012-08-01 2012-07-30 4 HGSI HUMAN GENOME SCIENCES INC
Employee Stock Option - Right to Buy
D - Sale to Issuer -128,118 0 -100.00 14.25 -1,825,682
2012-08-01 2012-07-30 4 HGSI HUMAN GENOME SCIENCES INC
Employee Stock Option - Right to Buy
D - Sale to Issuer -137,340 0 -100.00 14.25 -1,957,095
2012-08-01 2012-07-30 4 HGSI HUMAN GENOME SCIENCES INC
Employee Stock Option - Right to Buy
D - Sale to Issuer -114,147 0 -100.00 14.25 -1,626,595
2012-08-01 2012-07-30 4 HGSI HUMAN GENOME SCIENCES INC
Employee Stock Option - Right to Buy
D - Sale to Issuer -115,010 0 -100.00 14.25 -1,638,892
2012-08-01 2012-07-30 4 HGSI HUMAN GENOME SCIENCES INC
Common Stock
U - Other -19,576 0 -100.00 14.25 -278,958
2012-08-01 2012-07-30 4 HGSI HUMAN GENOME SCIENCES INC
Common Stock
U - Other -68,701 0 -100.00 14.25 -978,989
2012-07-26 2012-07-24 4 HGSI HUMAN GENOME SCIENCES INC
Employee Stock Option - Right to Buy
M - Exercise -10,696 104,304 -9.30
2012-07-26 2012-07-24 4 HGSI HUMAN GENOME SCIENCES INC
Employee Stock Option - Right to Buy
M - Exercise -12,610 87,390 -12.61
2012-07-26 2012-07-24 4 HGSI HUMAN GENOME SCIENCES INC
Employee Stock Option - Right to Buy
M - Exercise -21,882 128,118 -14.59
2012-07-26 2012-07-24 4 HGSI HUMAN GENOME SCIENCES INC
Employee Stock Option - Right to Buy
M - Exercise -12,660 137,340 -8.44
2012-07-26 2012-07-24 4 HGSI HUMAN GENOME SCIENCES INC
Employee Stock Option - Right to Buy
M - Exercise -10,853 114,147 -8.68
2012-07-26 2012-07-24 4 HGSI HUMAN GENOME SCIENCES INC
Common Stock
M - Exercise 10,696 88,277 13.79 9.35 100,018 825,478
2012-07-26 2012-07-24 4 HGSI HUMAN GENOME SCIENCES INC
Common Stock
M - Exercise 10,853 77,581 16.26 10.62 115,259 823,910
2012-07-26 2012-07-24 4 HGSI HUMAN GENOME SCIENCES INC
Common Stock
M - Exercise 12,610 66,728 23.30 10.89 137,323 726,668
2012-07-26 2012-07-24 4 HGSI HUMAN GENOME SCIENCES INC
Common Stock
M - Exercise 12,660 54,118 30.54 4.92 62,287 266,261
2012-07-26 2012-07-24 4 HGSI HUMAN GENOME SCIENCES INC
Common Stock
M - Exercise 21,882 41,458 111.78 0.52 11,379 21,558
2012-07-02 2012-06-29 4 SNSS SUNESIS PHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 25,000 25,000
2012-03-12 2012-03-10 4 HGSI HUMAN GENOME SCIENCES INC
Employee Stock Option - Right to Buy
A - Award 108,000 108,000
2012-01-05 2012-01-03 4 DNDN DENDREON CORP
Common Stock
A - Award 25,000 32,047 354.76
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)